New abstracts show the oral PCSK9 inhibitor cut LDL-C by 57% to 63% across PREVENT risk groups, with reductions maintained in an extension study.

The FDA granted accelerated approval to the first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis (RRP).

Facing steep 2027 cost increases, employers are narrowing obesity drug coverage, while direct-to-employer models let them cap ...

Patients on tegoprubart reported fewer transplant-related symptoms and better quality of life at 12 months than those on ...

In nearly 443,000 US adults, both low-frequency and heavy cannabis use were linked to higher odds of cardiovascular disease, led by stroke.

Karin Johnson, MD, says permanent daylight saving time won’t boost exercise or road safety and that sleep loss from spring ...

Nikhil C. Munshi, MD, says 25% to 30% of patients with myeloma may now be cured, but relapse and access remain challenges.

Cleveland Clinic's Beth Faiman, PhD, MSN, says fast-moving myeloma care requires funded education and fewer barriers for ...

Mayo Clinic case-control study links higher birth weight and childhood obesity to greater non-Hodgkin lymphoma risk, while ...

PBM reform, Medicare Advantage exits, and the 340B rebate pilot are reshaping drug access. Here is what payers need to know ...

T2D-2, retatrutide lowered A1C 2.2 points vs 1.8 with semaglutide 2 mg and more than doubled weight loss at 80 weeks.

A clinical-note analysis of more than 1000 patients found rising off-label BPC-157 use for pain and healing, with outcomes ...